Resolution criteria

This market resolves to YES if Dr. Bryan Roth is announced as a winner of a Nobel Prize (typically in Physiology or Medicine, or Chemistry) specifically for his work on DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) or chemogenetics.

The market will resolve to NO if he does not win the prize on or before the market's close date. If another set of researchers is awarded a Nobel Prize specifically for the development of chemogenetics/DREADDs without Bryan Roth being included as a co-laureate, the market will also resolve to NO.

The official announcements on the Nobel Prize website will serve as the source of truth.

Background

Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina at Chapel Hill. In the mid-2000s, his laboratory pioneered "DREADDs"—a widely-used chemogenetic platform utilizing engineered G protein-coupled receptors (GPCRs) that can be non-invasively controlled by synthetic, otherwise inert drugs. DREADDs have become standard tools in thousands of neuroscience laboratories worldwide to map and manipulate neural circuits controlling behavior, perceptions, and motor functions. Due to the transformative nature of chemogenetics in physiology, pharmacology, and neuroscience, the technology is often cited as a candidate for future Nobel-level recognition.

This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.